GlassScriptPhysician profile
Virind D Gupta
NPI 1154436889
$2,247.90
in general payments reported to CMS, 2019-2025
26 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $223 · 2021: $645 · 2022: $250 · 2023: $228 · 2024: $186 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.03 | 2021-2025 | |
| Allergan, INC. | $249.68 | 2019 | |
| Collegium Pharmaceutical, INC. | $128.62 | 2019-2021 | |
| Alkermes, INC. | $127.17 | 2023 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $122.75 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $117.80 | 2020 | |
| Sunovion Pharmaceuticals INC. | $117.47 | 2019 | |
| Paratek Pharmaceuticals, INC. | $116.56 | 2021-2022 | |
| Nalu Medical, INC. | $110.65 | 2021 | |
| Mdd US Operations, LLC | $104.24 | 2021 | |
| Boston Scientific Corporation | $91.97 | 2025 | General - Pain Management |
| Medtronic, INC. | $72.57 | 2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $62.41 | 2022 | |
| Grt US Holding, INC. | $53.75 | 2022 | |
| Pfizer INC. | $48.64 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $36.39 | 2021 | |
| Lilly USA, LLC | $28.15 | 2024 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $20.63 | 2024 | |
| Emergent Biosolutions INC. | $20.34 | 2019 | |
| Daiichi Sankyo INC. | $17.64 | 2019 | |
| Eisai INC. | $16.12 | 2020 | |
| Genentech USA, INC. | $16.05 | 2020 | |
| Horizon Therapeutics Plc | $16.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2024 | Relistor |
| Indivior INC. | $14.17 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.81 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virind Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.